Table 1.
Summary of Clinical Studies Using Cannabinoids to Treat Dermatological Conditions
| Study | Type of study | N | Cannabinoid | Outcome |
|---|---|---|---|---|
| Acne | ||||
| Ali and Akhtar1 | Single blind compare | 11 | 3% Cannabis sativa extract cream | Significant decrease in sebum and erythema (p<0.05) |
| Aesteatoic eczema | ||||
| Yuan et al.23 | RCT | 60 | Emollient with PEA/AEA | PEA/AEA associated with improved scaling, dryness, and itching at day 28 (p<0.05), but no difference in transepidermal water loss |
| Atopic dermatitis | ||||
| Callaway et al.26 | Single blind crossover | 20 | Dietary hempseed oil | Improvement of skin dryness and itchiness (p<0.05), decrease in dermal medication usage (p<0.05) |
| Del Rosso25 | Investigator-blinded compare | 43 | PEA-containing nonsteroidal cream | Lengthened the mean time to the next flare on an average of 28 days |
| Eberlein et al.24 | Cohort | 2456 | PEA-containing cream | Improvement in symptoms, decreased use of topical steroids, improved sleep (p<0.001) |
| Chronic pruritus | ||||
| Dvorak et al.19 | Double blinded compare | 12 | Cannabinoid receptor agonist HU210 by skin patch | Reduced experimentally induced itch (p<0.05), attenuated an increase in blood flow (p<0.003) |
| Ständer et al.21 | Cohort | 22 | Emollient with PEA | Reduced subjective severity of itch (p≤0.05) |
| Visse et al.22 | Single blind compare | 100 | PEA | No significant differences between PEA and control in itch, quality of life, or cosmetic acceptance |
AEA, anandamide; PEA, N-palmitoylethanolamide; RCT, randomized controlled trials.